BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10700572
• 负责人: SUBHRA MOHAPATRA
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10700572
• 关键词: 3-Dimensional; Academy; Acute; Affect; Alzheimer' s disease related dementia; American; Anti-Inflammatory Agents; Appointment; Area; Artificial Intelligence; Award; Biomedical Engineering; Biopsy; Biotechnology; CCL20 gene; COVID-19; COVID-19 patient; COVID-19 treatment; Cell Therapy; Cell model; Cells; Chronic; Chronic Disease; Clinical Research; Clinical Trials; Collaborations; Colorectal Cancer; Communicable Diseases; Data; Dedications; Dendrimers; Development; Developmental Therapeutics Program; Diagnostic; Disease; Drug Packaging; Drug Targeting; Entrepreneurship; Extramural Activities; Faculty; Florida; Funding; General Population; Graduate Education; Health; Healthcare; Hospitals; Human; Immunocompetent; In Vitro; Incidence; Individual; Industry Collaboration; Inflammation; International; Investigation; Journals; Leadership; Legal patent; Licensing; Literature; Long COVID; Lung diseases; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Medicine; Mentors; Mesenchymal Stem Cells; Modeling; Molecular; Molecular Medicine; Mus; Nerve Regeneration; Neurocognitive; Neurodegenerative Disorders; Oligosaccharides; Oncolytic; Pathogenesis; Population; Property; Publications; Research; Research Activity; Research Personnel; Research Support; Respiratory Syncytial Virus Infections; SARS-CoV-2 antiviral; SARS-CoV-2 infection; Safety; Scientist; Services; Small Interfering RNA; System; Testing; Therapeutic; Therapeutic Research; Time; Training; Translational Research; Traumatic Brain Injury; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Viral; Viral Respiratory Tract Infection; Virus Diseases; Virus Replication; X-Ray Computed Tomography; career; chest computed tomography; clinical diagnosis; clinical diagnostics; college; combinatorial; coronavirus disease; cytokine release syndrome; efficacy evaluation; human disease; improved; in vivo; indexing; inhibitor; innovation; malignant breast neoplasm; mouse model; nano; nanoformulation; nanomedicine; nanoparticle; nanoscale; nanotherapeutic; nervous system disorder; novel; novel diagnostics; novel virus; pandemic disease; particle; prognostic; programs; prophylactic; research clinical testing; senior faculty; stem cell therapy; therapeutically effective

This proposal seeks to renew Research Career Scientist Award held by Dr. Subhra Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2018. She is also a tenured- full professor (part-time) at the VA-affiliated academic center- the University of South Florida. She is the recipient of several international/national awards and recognitions including as a Fellow of the National Academy of Inventors and a Fellow of the American Institute for Medical and Biological Engineering. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 2007 and has been continuously funded with the Merit Review Award focused on cancer, traumatic brain injury (TBI), and COVID since 2016. She has been studying the basic molecular and translational mechanisms underlying the inflammation in diverse acute/chronic diseases including COVID-19, cancers, and TBI, all of which afflict VA population and contribute significantly to the overall health of the Veterans. The main premise of her research program has been to understand the mechanisms involved in the disease pathogenesis toward developing novel diagnostic/prognostic and therapeutic approaches to treat them. Current and ongoing research activities to be supported by this RCS Award focus on three areas. The first program centers on the characterization of novel virus-neutralizing nanoparticles that may serve as prophylactic and/or treatment for COVID-19 patients. In this proposal, these particles will be investigated for their potential and validated in relevant human cellular and mouse models. She is collaborating with other VA investigators in developing an additional project to develop novel siRNA-based prophylactic and therapeutic approaches targeting viral replication and cytokine storm that follows acute SARS- CoV-2 infection. The second research program focuses on the investigation of a novel combinatorial therapeutic approach in a mouse model of moderate TBI that includes an intranasal dendrimer-based nano-formulated siRNA treatment against a recently discovered target, CCL20 to reduce inflammation, and a parallel treatment to promote neuroregeneration by therapy with mesenchymal stem cells. In the third research program Dr. Mohapatra’s lab aims to investigate and test a novel targeted oncolytic viro-cell therapy for lung cancer using the mesenchymal stem cells infected by a respiratory syncytial virus infection, which is harmless for immunocompetent individuals. This project uses a 3D multicell tumoroid in vitro and biopsy-derived cultures ex vivo, which her lab has pioneered. Further, this project uses in vivo mouse models of lung cancer to evaluate the safety and efficacy of oncolytic viro-cell therapy. The project to date has attracted industry collaboration, which might lead to clinical trials. Overall, these highly innovative approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for diverse diseases of Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. With ~100 publications, 20 patents, an h- index of 36 and an i-index of 85, Dr. Subhra Mohapatra is recognized nationally and internationally for her contributions to the fields of research on cancer, neurodegenerative disease, and viral infections. She has received substantial extramural research support including awards from the NIH, ONR, Department of Veterans Affairs, and Florida Department of Health. It is anticipated that the development of these effective therapeutics will greatly improve the quality of Veteran’s healthcare.

该提案旨在延续 Subhra 博士持有的研究职业科学家奖 Mohapatra，自 2018 年起在佛罗里达州坦帕市的 James A. Haley VA 医院工作。她也是一名终身教授 她是退伍军人管理局附属学术中心——南佛罗里达大学的全职教授（兼职）。 获得多项国际/国家奖项和认可，包括作为院士 美国国家发明家学院院士和美国医学与生物研究所院士 自那时起，Mohapatra 博士一直担任 VA 医院（医学）的研究员。 2007 年，并持续获得优异评审奖，重点关注癌症、创伤 自2016年以来，她一直在研究脑损伤（TBI）和新冠病毒的基础分子和 多种急性/慢性疾病炎症的转化机制，包括 COVID-19、癌症和 TBI，所有这些都会影响 VA 人群，并对 她的研究计划的主要前提是退伍军人的整体健康。 了解疾病发病机制，以开发新的 当前和正在进行的研究的诊断/预后和治疗方法。 RCS 奖支持的活动主要集中在三个领域。 新型病毒中和纳米颗粒的表征，可用作预防和/或 在该提案中，将研究这些颗粒的潜力。 并在相关的人类细胞和小鼠模型中得到验证。她正在与其他 VA 合作。 研究人员正在开发一个额外的项目来开发基于 siRNA 的新型预防剂和 针对急性 SARS 后的病毒复制和细胞因子风暴的治疗方法 第二个研究项目重点研究一种新型冠状病毒感染。 中度 TBI 小鼠模型的组合治疗方法，包括鼻内注射 基于树枝状聚合物的纳米制剂 siRNA 治疗针对最近发现的靶标 CCL20 减少炎症，并并行治疗以促进神经再生 在第三个研究项目中，Mohapatra 博士的实验室旨在研究间充质干细胞。 并使用间充质干细胞测试一种新型靶向溶瘤病毒细胞疗法治疗肺癌 被呼吸道合胞病毒感染的细胞，对免疫功能健全的人无害 该项目使用体外 3D 多细胞肿瘤和离体活检衍生的培养物， 此外，该项目还利用肺癌小鼠体内模型来进行研究。 评估溶瘤病毒细胞疗法的安全性和有效性该项目迄今为止已吸引了众多关注。 总体而言，这些高度创新的行业合作可能会导致临床试验。 综合起来的方法预计将产生具有高影响力的临床诊断和治疗 为退伍军人和其他需要帮助的美国人的各种疾病提供帮助。 受大流行影响的比例较大，并且越来越多地受到肺病发病率的影响 与一般人群相比，癌症和 TBI 拥有约 100 篇出版物、20 项专利、一项 h-。 Subhra Mohapatra 博士的指数为 36，i 指数为 85，受到全国认可， 国际表彰她对癌症、神经退行性疾病研究领域的贡献 她获得了大量的校外研究支持，包括奖项。 来自 NIH、ONR、退伍军人事务部和佛罗里达州卫生部。 预计这些有效疗法的开发将大大提高治疗质量 退伍军人的医疗保健。

项目成果

Elevated potassium outward currents in hyperoxia treated atrial cardiomyocytes.

高氧处理的心房心肌细胞中钾外向电流升高。

• 发表时间: 2018
• 影响因子: 5.6
• 作者: Vysotskaya, Zhanna;Chidipi, Bojjibabu;Rodgers, Jennifer L;Tang, Xiaolan;Samal, Eva;Kolliputi, Narasaiah;Mohapatra, Subhra;Bennett, Eric S;Panguluri, Siva K
• 通讯作者: Panguluri, Siva K

Potential of mesenchymal stem cells alone, or in combination, to treat traumatic brain injury.

间充质干细胞单独或联合治疗创伤性脑损伤的潜力。

• 发表时间: 2020
• 影响因子: 5.5
• 作者: Willing, Alison E;Das, Mahasweta;Howell, Mark;Mohapatra, Shyam S;Mohapatra, Subhra
• 通讯作者: Mohapatra, Subhra

Molecular mechanism-driven new biomarkers and therapies for atopic dermatitis.

分子机制驱动的特应性皮炎新生物标志物和疗法。

• 发表时间: 2020
• 作者: Mohapatra, Shyam S;Mohapatra, Subhra;McGill, Andrew R;Green, Ryan
• 通讯作者: Green, Ryan

Sertoli Cells Loaded with Doxorubicin in Lipid Micelles Reduced Tumor Burden and Dox-Induced Toxicity.

在脂质胶束中负载阿霉素的支持细胞可减少肿瘤负荷和阿霉素诱导的毒性。

• 发表时间: 2017-10
• 影响因子: 3.3
• 作者: Das, Mahasweta;Howell, Mark;Foran, Elspeth A;Iyre, Rohit;Mohapatra, Shyam S;Mohapatra, Subhra
• 通讯作者: Mohapatra, Subhra

Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats.

移植前的吡格列酮治疗可提高大鼠脑外伤后人类间充质干细胞的功效。

• 发表时间: 2019-09-20
• 影响因子: 4.6
• 作者: Das, Mahasweta;Mayilsamy, Karthick;Tang, Xiaolan;Han, Jung Yeon;Foran, Elspeth;Willing, Alison E;Mohapatra, Shyam S;Mohapatra, Subhra
• 通讯作者: Mohapatra, Subhra